The introduction of dolutegravir into more health programs in Colombia depends on the government’s purchase of generic doses and the speed of the process. It typically takes at least six months for generics to be registered and made available. The Global Humanitarian Progress Corporation has encouraged the Colombian government to buy doses as soon as possible, allowing patients access while the drug is still under patent. The rights held by ViiV Healthcare for dolutegravir in Colombia are set to expire in 2026, paving the way for generic versions.
Some advocates are skeptical about Colombia’s ability to efficiently purchase and distribute dolutegravir due to past experiences with shortages of other medications. Nestor Alvarez Lara, president of the advocacy group High Cost Patients, called for a well-planned rollout to avoid similar issues. He emphasized the importance of buying in large quantities to ensure a continuous supply and avoid running out of medication. The Colombian Ministry of Health and Social Protection is finalizing negotiations to purchase a continuous supply of dolutegravir through the Pan American Health Organization, with plans to make it available by the end of 2024.
One person who has benefited from switching to dolutegravir is Villan, who noticed a positive transformation in his mental state after switching medications. He credits the change to his improved relationship with his husband and hopes that the new license for dolutegravir will expand access and eliminate uncertainties faced by people with HIV. Villan has also helped friends access dolutegravir when their health insurance ran out, emphasizing the importance of continuous treatment for effectiveness. He believes that having confidence and consistency in treatment allows individuals to live an undetectable life.
The Colombian government’s plan to purchase over 800,000 bottles of dolutegravir, providing a year of treatment for approximately 67,000 people, is a significant step towards expanding access to the drug. The government aims to have dolutegravir available by the last three months of 2024, ensuring a continuous supply for those in need. This effort aligns with the goal of improving HIV treatment and care in the country, potentially benefiting thousands of individuals like Villan who rely on dolutegravir for their health and well-being.
Despite concerns raised by advocates about past procurement challenges, the Colombian government’s commitment to securing a continuous supply of dolutegravir through international partnerships is a positive development. By purchasing large quantities of the drug, officials aim to prevent shortages and ensure sustained access for people living with HIV. Initiatives like these are essential in addressing health disparities and improving outcomes for individuals who rely on dolutegravir for their treatment. Through effective planning and coordination, Colombia can enhance its healthcare system and provide better support for those in need of vital medications like dolutegravir.
